Literature DB >> 4212012

Fibrin degradation products in the serum and cerebrospinal fluid of patients with group A meningococcal meningitis.

M J Brueton, P Tugwell, H C Whittle, B M Greenwood.   

Abstract

Forty-one patients suffering from group A meningococcal meningitis in an area within the epidemic meningococcal belt of tropical West Africa were studied. The serum of only two of these patients contained fibrin degradation products (FDPs). The cerebrospinal fluid of 21 of these cases was also examined for FDPs, which were present in 13. Their presence in the cerebrospinal fluid was associated with a poor prognosis.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4212012      PMCID： PMC478135          DOI： 10.1136/jcp.27.5.402

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  10 in total

1.  The epidemic of cerebrospinal fever in the northern provinces of Nigeria, 1949-1950.

Authors:  D W HORN
Journal:  J R Sanit Inst       Date:  1951-09

2.  The normal platelet count and platelet factor 3 availability in some Nigerian population groups.

Authors:  E M Essien; E A Usanga; O Ayeni
Journal:  Scand J Haematol       Date:  1973

3.  Counter-current immunoelectrophoresis in the diagnosis of meningococcal infections.

Authors:  B M Greenwood; H C Whittle; O Dominic-Rajkovic
Journal:  Lancet       Date:  1971-09-04       Impact factor: 79.321

4.  Thrombocytopenia and bleeding complications in severe cases of meningococcal infection treated with heparin, dextran 70 and chlorpromazine.

Authors:  P M Niklasson; M Blombäck; P Lundbergh; T Strandell
Journal:  Scand J Infect Dis       Date:  1972

5.  Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.

Authors:  J I Brody
Journal:  J Clin Pathol       Date:  1972-09       Impact factor: 3.411

6.  Intravascular coagulation in fulminant meningococcemia.

Authors:  W G McGehee; S I Rapaport; P F Hjort
Journal:  Ann Intern Med       Date:  1967-08       Impact factor: 25.391

7.  Meningeal vascular thrombosis and inflammation in pneumococcal meningitis.

Authors:  L G Dickson; M W Yassin
Journal:  J Egypt Public Health Assoc       Date:  1969

8.  Fulminant meningococcemia and disseminated intravascular coagulation.

Authors:  A Winkelstein; C L Songster; T S Caras; H H Berman; W L West
Journal:  Arch Intern Med       Date:  1969-07

9.  Fatal intravascular consumption coagulopathy in meningococcal sepsis.

Authors:  R W Evans; B Glick; F Kimball; M Bobell
Journal:  Am J Med       Date:  1969-06       Impact factor: 4.965

10.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113
  10 in total
  6 in total

1.  Paediatric research society.

Authors: 
Journal:  Arch Dis Child       Date:  1976-03       Impact factor: 3.791

2.  Fibrin-fibrinogen degradation products in cerebrospinal fluid.

Authors:  M J Brueton; G R Breeze; J Stuart
Journal:  J Clin Pathol       Date:  1976-04       Impact factor: 3.411

3.  The complications and management of meningococcal meningitis.

Authors:  J M Shneerson; I W Fawcett
Journal:  Intensive Care Med       Date:  1979-03       Impact factor: 17.440

4.  Coagulation and fibrinolytic activity of cerebrospinal fluid.

Authors:  M Anderson; K B Matthews; J Stuart
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

5.  Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).

Authors:  H Fodstad; I M Nilsson
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

6.  Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.

Authors:  H Fodstad; A Pilbrant; M Schannong; S Strömberg
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.